Identification of microbiome-based biomarkers for end-stage liver disease
The end stage of liver disease is decompensated cirrhosis and progression towards acute-on-chronic liver failure (ACLF), which presents with systemic inflammation and organ failure and has a dismal prognosis. Emerging evidence indicates that the gut microbiome is implicated in liver cirrhosis, but the underlying mechanism remains to be elucidated. MICROB-PREDICT is a programme of excellence funded by the EU that aims to investigate the role of the microbiome in the gut–liver interaction. Researchers will also identify microbiome-based biomarkers associated with end-stage liver disease and generate data from large patient cohorts. Collectively, this information will enable accurate patient stratification and pave the way for personalised therapies.
Call for proposal
See other projects for this call
Funding SchemeRIA - Research and Innovation action